Wird geladen...
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
Methotrexate (MTX) is recognized as the anchor drug in the algorithm treating chronic arthritis (RA, psoriatic arthritis), as well as a steroid sparing agent in other inflammatory conditions (polymyalgia rheumatica, vasculitis, scleroderma). Its main mechanism of action has been related to the incre...
Gespeichert in:
| Veröffentlicht in: | J Leukoc Biol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852123/ https://ncbi.nlm.nih.gov/pubmed/31313387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/JLB.5RU0519-145R |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|